Skip to main content

Table 2 Characteristics of all CVST-patients, all CVST-patients with Follow-up Data, CVST- patients without IH and with IH. Age is expressed as median (min-max) with *Mann-Whitney-U-Test, categorical data expressed as n (%) with Chi-Square-Test

From: Chronic intracranial hypertension after cerebral venous and sinus thrombosis – frequency and risk factors

  All CVST
(n = 102)
All CVST with Follow-up Data (n = 70) CVST without IH
(n = 63)
CVST with IH
(n = 7)
p-value
Gender female 75 (73.5%) 51 (72.9%) 46 (73%) 5 (71.4%) 0.93
Age, years 40.5 (17–77) 40.5 (17–77) 41 (17–77) 40 (19–67) 0.83*
Symptoms and signs
 Headache 84 (82.4%) 58 (82.9%) 52 (82.5%) 6 (85.7%) 0.83
 Isolated headache 23 (22.5%) 19 (27.1%) 17 (27%) 2 (28.6%) 0.93
 Visual disturbance 20 (19.6%) 17 (24.3%) 13 (20.6%) 4 (57.1%) 0.03
 Paresis 25 (24.5%) 16 (22.9%) 15 (23.8%) 1 (14.3%) 0.57
 Aphasia 16 (15.7%) 7 (10%) 7 (11.1%) 0.35
 Focal seizures 14 (13.7%) 12 (17.1%) 11 (17.5%) 1 (14.3%) 0.80
 Seizure with generalization 23 (22.6%) 12 (17.1%) 12 (19%) 0.20
 Any seizure 37 (36.3%) 26 (37.1%) 25 (39.7%) 1 (14.3%) 0.19
 Mental status disorder 14 (13.7%) 8 (11.4%) 7 (11.1%) 1 (14.3%) 0.80
 Disturbed consciousness 13 (12.7%) 4 (5.7%) 4 (6.3%) 0.49
CT/MR findings
 Infarct one hemisphere 19 (18.6%) 11 (15.7%) 11 (17.5%) 0.23
 Infarct both hemispheres 5 (4.9%) 2 (2.9%) 2 (3.2%) 0.63
 Hemorrhage one hemisphere 35 (34.3%) 21 (30%) 18 (28.6%) 3 (42.9%) 0.43
 Hemorrhage both hemispheres 9 (8.8%) 4 (5.7%) 4 (6.3%) 0.49
Occluded sinus/vein
 Superior sagittal sinus 43 (42.5%) 30 (42.9%) 28 (44.4%) 2 (28.6%) 0.42
 One/Both lateral sinus 75 (73.5%)/7 (6.9%) 53 (75.7%)/5 (7.1%) 47 (74.6%)/4 (6.3%) 6 (85.7%)/1 (14.3%) 0.52 / 0.44
 Straight sinus 14 (13.7%) 9 (12.9%) 8 (12.7%) 1 (14.3%) 0.91
 Inner cerebral veins 8 (7.8%) 3 (4.3%) 3 (4.8%) 0.56
 Cortical veins 23 (22.6%) 17 (24.3%) 16 (25.3%) 1 (14.3%) 0.52
 Jugular veins 36 (35.3%) 28 (40%) 24 (38.1%) 4 (57.2%) 0.33
 Multiple thrombosis in more than one dural sinus/vein 62 (60.8%) 48 (68.6%) 43 (68.3%) 5 (71.4%) 0.86
 Thrombus extending from lateral sinus into jugular vein 34 (33.3%) 27 (38.6%) 23 (36.5%) 4 (57.2%) 0.29
Risk factors
 Thrombophilia 28 (27.5%) 20 (28.6%) 19 (30.2%) 1 (14.3%) 0.38
 Malignancy 11 (10.8%) 5 (7.1%) 4 (6.3%) 1 (14.3%) 0.44
 Pregnancy 1 (1%) 1 (1.4%) 1 (1.6%) 0.74
 Puerperium 1 (1%)
 Oral contraceptives 25 (24.5%) 21 (30%) 19 (30.2%) 2 (28.6%) 0.93
 Vaginal ring 6 (5.9%) 6 (8.6%) 6 (9.5%) 0.39
 Steroid therapy 13 (12.7%) 9 (12.9%) 9 (14.3%) 0.28
 Cytotoxic therapy 8 (7.8%) 4 (5.7%) 4 (6.3%) 0.49
 Smoking 9 (8.8%) 7 (10%) 6 (9.5%) 1 (14.3%) 0.69
 Head injury 4 (3.9%) 3 (4.3%) 3 (4.8%) 0.56
Treatment – acute phase
 LMWH 74 (72.5%) 55 (78.6%) 49 (77.8%) 6 (85.7%) 0.63
 Heparine i.v. 24 (23.5%) 13 (18.6%) 13 (20.6%) 0.18
 Hemicraniectomy 7 (6.9%) 4 (5.7%) 4 (6.3%) 0.49
 Mechanical thrombectomy 11 (10.8%) 4 (5.7%) 3 (4.8%) 1 (14.3%) 0.30
Treatment – post-acute phase
 OAK 39 (38.2%) 29 (41.4%) 26 (41.3%) 3 (42.9%) 0.94
 NOAK 44 (43.1%) 35 (50%) 31 (49.2%) 4 (57.1%) 0.69
 Rivaroxaban 25 (24.5%) 21 (30%) 19 (30.2%) 2 (28.6%) 0.93
 Dabigatran 18 (17.6%) 13 (18.6%) 12 (19%) 1 (14.3%) 0.76
Outcome at discharge
 mRS 0–2 at discharge 75 (73.5%) 58 (82.9%) 51 (81%) 7 (100%) 0.20
Outcome at follow-up
 mRS 0–2 at follow-up   65 (92.9%) 58 (92.1%) 7 (100%) 0.44
 Complete recanalization   18 (25.7%) 16 (25.4%) 2 (28.6%) 0.86
 Partial recanalization   47 (67.1%) 44 (69.8%) 3 (42.9%) 0.15
 No recanalization   5 (7.1%) 3 (4.8%) 2 (28.6%) 0.02
 Recurrent sinus thrombosis   6 (8.6%) 2 (3.2%) 4 (57.1%) < 0.001